as 12-18-2024 9:44am EST
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
Founded: | 1991 | Country: | United States |
Employees: | N/A | City: | SAN FRANCISCO |
Market Cap: | 3.3M | IPO Year: | 1996 |
Target Price: | N/A | AVG Volume (30 days): | 28.0K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -6.67 | EPS Growth: | N/A |
52 Week Low/High: | $3.24 - $14.80 | Next Earning Date: | 12-27-2024 |
Revenue: | $3,000 | Revenue Growth: | -99.24% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
TTNP Breaking Stock News: Dive into TTNP Ticker-Specific Updates for Smart Investing
GlobeNewswire
21 days ago
MT Newswires
4 months ago
MT Newswires
4 months ago
MT Newswires
4 months ago
MT Newswires
4 months ago
GlobeNewswire
4 months ago
Associated Press Finance
4 months ago
MT Newswires
6 months ago
The information presented on this page, "TTNP Titan Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.